Anemias hemolíticas autoinmunes, diagnóstico y tratamiento
Revista Hematología ENERO - ABRIL 2020
pdf

Palabras clave

Anemia hemolítica autoinmune, Anemia hemolítica asociada a drogas, autoanticuerpos, tratamiento.

Cómo citar

Maldonado Rojas, M. A., & Toro Opazo, C. (2020). Anemias hemolíticas autoinmunes, diagnóstico y tratamiento. Revista Hematología, 24(1), 70–80. Recuperado a partir de http://revistahematologia.com.ar/index.php/Revista/article/view/217

Resumen

La anemia hemolítica autoinmune es causada por anticuerpos que están dirigidos contra los eritrocitos del propio organismo. En esta revisión se abordan las AHAI causadas por anticuerpos de tipo IgG, IgM, anticuerpos bifásicos y secundarios al uso de medicamentos. Se consideran aspectos etiológicos y fisiopatológicos, el diagnóstico y tratamientos necesarios para los distintos trastornos causantes.
Finalmente se presenta una conclusión, donde se manifiesta que en el diagnóstico, el fundamento del test anti globulina, con innovación en técnicas para su realización, continúa como principal prueba para su estudio, lo que confirma su eficacia, y en cuanto a tratamiento, los corticoides siguen siendo el tratamiento de primera línea y surgen pautas de tratamientos avaladas por estudios de casos, que muestran la efectividad de los anticuerpos monoclonales anti CD20, transformándolos en agentes terapéuticos de segunda línea.

pdf

Citas

1. Lichtman MA, Williams Hematology. 7ma ed. New York: McGraw-Hill, 2006.
2. Palomo I, Vásquez M, Armanet L. Anemias hemolíticas. In: Palomo I, Pereira J, Palma J, editors. Hematología,
fisiopatología y diagnóstico. 1ª ed. Talca: Universidad de Talca, 2005.
3. Das S, Chakrabarty R, Zaman R. Immunohematological and clinical characterizations of mixed autoimmune hemolytic anemia. Asian J Transfus Sci. 2018;12: 99-104. https://doi.org/10.4103/ajts.AJTS_105_17
4. Valent P, Lechner K. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wien. Klin. Wochenschr; 2008; 120:136-51. https://doi.org/10.1007/500508-008-0945-1.
5. Barcellini W. Immune hemolysis: diagnosis and treatment recommendations. Semin Hematol. 201552:304-12. https://doi.org/10.1053./j.seminhematol.2015.05.001
6. Li BJ, Yuan X, Jiang YJ, Ning-Li, Shu XW, Liu KL. Retrospective analysis of 30 severe autoimmune hemolytic anemia patients treated by whole blood exchange transfusion. Transfusion. 2015; 55: 2231-7. https://doi.org/10.1111/trf.13122.
7. Rigal D. Meyer F. Anémies hémolytiques auto-immunes: diagnostic biologique et nouvelles approches thérapeutiques. Transfusion Clinique et Biologique. 2011; 18: 277- 85. https://doi.org/10.1016/j.tracli.2011.03.002.
8. Eaton W, Rose N, Kalaydjian A, Pedersen M, Mortenses P. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007;29:1-9. https://doi.org/10.1016/j.aut.2007.05.002.
9. López M. Anemias hemolíticas autoinmunes. Rev Medicina General y de la familia. 2010;127:186-91.
10. Alfonso, M. Bencomo. Tratamiento de las anemias hemolíticas autoinmunes. Rev Cubana Hematol Inmunol
Hemoter. 2013;29(4):327-39.
11. Clinton J. Síndrome de anemia hemolítica. (Revisión bibliográfica). Rev Médica de Costa Rica y Centroamérica.
2008. LXV (583) 85-90.
12. Zantek N, Koepsell S, Tharp Jr D and Cohn C. The direct antiglobulin test: A critical step in the evaluation of hemolysis. Am J Hematol. 2012. 87:707-9. https://doi.org/10.1002/ajh.23218.
13. Fayek MH, Saad AA, Eissa DG, Tawfik LM, Kamal G. Role of gel test and flow cytometry in diagnosis of Coombs' negative autoimmune haemolytic anaemia.
Int J Lab Hematol. 2012;34:311-9. https://doi.org/10.1111/j.1751-553X.2011.01397.
14. Bloch M, Sakac D, Branch H, Cserti-Gazdewich C, Pendergrast J, Pavenski K et al. Western immunoblotting as a new tool for investigating direct antiglobulin test-negative autoimmune hemolytic anemias. Transfusion. 2015;55:1529-37. https://doi.org/10.1111/trf.13082.
15. Jaime-Pérez J, Almaguer-Gaona C. Rediscovering the Coombs test. Medicina Universitaria. 2016;18:185-6. https://doi.org/10. 1016/j.rmu.2016.07.001.
16. Arndt P, Leger R, Garratty G. Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. Transfusion. 2009; 49:235-42. https://doi.org/10. https://doi.org/10. 1111/j.1537-2995.2008.0195.
17. Alfonso M, Bencomo A, Espinoza E, Guerrero R, Guerra E et al. Caracterización de pacientes adultos
con anemia hemolítica autoinmune atendidos en instituto de hematología e inmunología. Rev Cubana Hematol Inmunol Hemoter. 2009; 25: 45-5.
18. Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA. Evidence based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood. 2011;118: 4036-40. https://doi.org/10. 1182/blood-2011-05-347708.
19. Diagnóstico. Anemia hemolítica autoinmune, http://www.fihu-diagnostico.org.pe/revista/numeros/2005/jul-set05/141-144.html; 2005 [consultada el 12 de marzo de 2019)].
20. DeLoughery T. Immune Hemolytic Anemia, Hospital Physician Board Review Manual. Hematology. 2013; 8. [consultada el 18 de mayo de 2019)].
21. Berentsen S, Sundic T, Hervig G, Tjønnfjord E. Autoimmun hemolytisk anemi. Medsin Og Vitenskap. Tidsskr Nor Legeforen. 2009;21:2226-31. https://doi.org/10. 4045/tidsskr.09.0161.
22. Obstetrics and Gynecology. A Case of Pregnancy Complicated with Evans Syndrome with Sequential Development of Autoimmune Warm Antibody Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura, https://www.hindawi.com/journals/
criog/2019/2093612/; 2019 [consultada el 12 de marzo de 2019)].
23. Zeerleder S. Autoimmune haemolytic anaemia - a practical guide to cope with a diagnostic and therapeutic challenge. Journal of Medicine. 2011;69:177-84.
24. Vásquez M, Maldonado M. Sistemas sanguíneos eritrocitarios de importancia clínica. 1ª Ed. Talca. Universidad de Talca. 2013.
25. Marinovic MA. Immunodeficiencies and their relation with autoimmune diseases. Rev Med Clin Condes.
2012;23(4):484-91.
26. Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2018; 30: 328-89. https://doi.org/10.1182/asheducation-2018.1.382.
27. Quintanilla J, Marchena M, Gourzong C. Síndrome de aglutininas frías. Acta Med costarric. 2004;46: 204-7.
28. Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009; 8:73-9. https://doi.org/10.1517/14740330802577351.
29. Encyclopedia of life sciences. Immune Haemolytic Anaemia, http://www.roitt.com/elspdf/Immune_Haemolytic_
Anaemia.pdf; 2005 [consultada el 12 de marzo de 2019].
30. Garratty G. Drug-induced immune hemolytic anemia. American Society of Hematology. 2009;1: 73 -9. https://doi.org/10.1182/asheducation-2009.1.73.
31. Johnson S, Fueger J, Gottschall J. One center’s experience: the serology and drugs associated with drug-induced
immune hemolytic anemia - a new paradigm. Transfusion. 2007; 47:697-702. https://doi.org/10.1111/j.1537-2995.2007.01173
32. Revista O.F.I.L Farmacovigilancia intensiva: Detección de anemia hemolítica inducida por cefalosporinas, http://www.revistadelaofil.org/wp-content/uploads/2014/01/OFILn14.pdf; 2004 [consultada el 12
de marzo de 2019].
33. Spath P, Garratty G, Petz L. Studies on the immune response to penicillin and cephalothin in humans. II.
Immunohematologic reactions to cephalothin administration. J Immunol. 1971;107:860-9.
34. Wouters D, Zeerleder S. Complement inhibitors to treat Ig M mediated autoimmune hemolysis. Haematologica.
2015;100:1388-95. https://doi.org/10.3324/haematol.2015.128538.
35. Lobuglio A, Cotran R, Jandl J. Red cells coated with immunoglobulin G: binding and sphering by mononuclear
cells in man. Science. 1967;158:2-5. https://doi.org/10.1126/science.158.3808.1582.
36. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemias. Blood. 2017;129:2971-9. https://
doi.org/10. 1182/blood-2016-11-693689.
37. Segel GB, Lichtman MA. Direct antiglobulin ("Coombs") test-negative autoimmune hemolytic anemia:
a review. Blood Cells Mol Dis. 2014;52:152-60. https://doi.org/10.1016/j.bcmd.2013.12.003.
38. Garratty G. Immune hemolytic anemia associated with negative routine serology, Semin Hematol. 2005; 42:156-64.
39. Bajpayee A, Dubey A, Verma RK, Chaudhary. A report of a rare case of autoimmune haemolytic anaemia in a patient with Hodgkin's disease in whom routine serology was negative. Blood Transfus. 2013;12:299-301 https://doi.org/10. 2450/2013.0292-12.
40. Meulenbroek E, Wouters D, Zeerleder S. Lyse or not to lyse: Clinical significance of red blood cell autoantibodies.
Blood Reviews. 2015;29:369-76. https://doi.org/10.1016/j.blre.2015.05.001.
41. Thedsawad AO, Taka W, Wanachiwanawin. Development of flow cytometry for detection and quantitation of red cell bound immunoglobulin G in autoimmune hemolytic anemia with negative direct Coombs test. Asian Pac J Allergy Immunol. 2011; 29: 364-7.
42. Chaudhary R, Das S, Gupta R and Khetan D. Application of flow cytometry in detection of red cell bound IgG
in Coombs negative AIHA. Hematology. 2006;11: 295-300 https://doi.org/10.1080/10245330600915958.
43. Garratty G. The James Blundell Award Lecture 2007: do we really understand immune red cell destruction?
Transfus Med. 2008;18:321-34. https://doi.org/10.1111/j.1365-3148.2008.00891.
44. Thomsen R, Schoonen W, Farkas D, Riis A, Fryzek J, Sorensen T. Risk of venous thromboembolism in
splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost. 2010;8:1413-6. https://doi.org/10. 1111/j.1538-7836.2010.03849.
45. Casan J, Wonga M, Northcottb J and Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Human Vaccines & Immunotherapeutics. 2018;14: 2820-41. https://doi.org/10. 1080/21645515.2018.1508624.
46. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99:1547-54. https://doi.org/10.3324/haematol.2014.114561,
47. Yong M, Thomsen R, Schoonen W, Farkas D, Riss A, Fryzek J et al. Mortality risk in splenectomised patients:
a Danish population-based cohort study. Eur J Intern Med. 2010;21:12-6. https://doi.org/10. 1016/j.ejim.2009.10.003.
48. D’Arena G, Califano C, Annunziata M, Tartarone A, Capalbo S, Villani O et al. Rituximab for warmtype idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol. 2007;79:53-8. https://doi.org/10. 1111/j.1600-
0609.2007.00861.x
49. Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffel A et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009; 266:484-91. https://doi.org/10.
1111/j.1365-2796.2009.02126.
50. Koppel A, Lim S, Osby M, Garratty G, Goldinfinger D. Rituximab as successful therapy in a patient with refractory paroxysmal cold hemoglobinuria. Transfusion. 2007:47:1902-4. https://doi.org/10. 1111/j.1537-2995.2007.01414.
51. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141:149-69. https://doi.org/10. 1111/j.1365-2141.2008.07054.
52. Fozza C, Longinotti M. Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas. Hindawi Publishing Corporation Advances in Hematology. 2011; htt1-4 https://doi.org/10.1155/2011/960137.
53. Peñalver F, Alvarez-Larrán A, Díez-Martin J, Gallur L, Jarque I, Caballero D et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol. 2010;89:1073-80. https://doi.org/10.1007/s00277-010-0997.
54. Karageorgas T Zomas A, Kazakou P, Katsimbri P, Mantzourani M, Boumpas D. Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematous. Rheumatology. 2016; 11:2085-7. https://doi.org/10. 1093/rheumatology/kew267.
55. Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH, Dastmalchi S. Affinity maturation and characterization of the ofatumumab monoclonal antibody. J Cell Biochem. 2019; 120: 940-50. https://doi.org/10.1002/jcb.27457.
56. Moyo VM, Smith D, Brodsky I, Crilley P, Jones Rj, Brodsky R. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. 2002;100: 704-6. https://doi.org/10.1182/blood-2002-01-0087.
57. Shvidel L, Sigler E, Shtalrid M, Berrebi A. Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: rethinking old cures. Am J Hematol. 2006;81:423-5. https://doi.org/10. 1002/ajh.20632.
58. Howard J, Hoffbrand A, Prentice H. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117:712-5.
59. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007; 21:511-4.
60. Alcaraz J. Abordaje del laboratorio de anemia hemolítica autoinmune (AHAI). Rev Mex Med Transf. 2009; 2:57-9. https://doi.org/10. 1038/sj.leu.2404512.61. Barros M, Langhi D, Bordin J. Autoimmune hemolytic anemia: transfusion challenges and solutions. Int J Clin Transfusion Medicine. 2017:5. https://doi.org/10.2147/IJCTM.S81870.
62. Berentsen S, Ulvestad E, Langholm R, Beiske K, Hansen H, Ghanima W, Sorbo J. Primary chronic cold
agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006:91:460-6. https://doi.org/10. 1080/10245330701445392.
63. Seok J, Wook J, Kook B, Chung J. The use of the complement inhibitor eculizumab (SolirisⓇ) treating Korean patients with paroxysmal nocturnal hemoglobinuria.
The Korean J Hematol. 2010;45: 269-74. https://doi.org/10. 5045/kjh.2010.45.4.269.
64. Cançado RD, Langhi Jr DM, Chiattone CS. Tratamento da anemia hemolítica auto-imune. Arq Med Hosp Fac Cienc Med Santa Casa São Paulo. 2004;50:56-60.
65. Nilsson P, Thomas A, Bergsethd G, Gustavsen A, Volokhinae E, van del Heuvel L et al. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses. Molecular Immunology. 2017; 80:111-4.https://doi.org/10.1016/j.molimm.2017.05.021.
66. Castaneda-Sanabria J, Hajage D, Le Jouan M, Perozziello A, Tubach F. Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol. 2016; 72:737-46 https://doi.org/10.1007/s00228-016-2027.
67. Tanaka H, Hashimoto S, Sugita Y, Sakai S, Takeda Y, Abe D et al. Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy. Int J Hematol. 2012; 96:501-5. https://doi.org/10. 1007/s12185-012-1158-y.
68. Schollkopf C, Kjeldsen L, Bjerrum O. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47:253-60. https://doi.org/10.

Todo el material publicado en la revista Hematología (versión electrónica y versión impresa), será cedido a la Sociedad Argentina de Hematología. De conformidad con la ley de derecho de autor (ley 11723) se les enviara a los autores de cada trabajo aceptado formulario de cesión de derechos de autor que deberá ser firmado por todos los autores antes de la publicación. Los autores deberán retener una copia del original pues la revista, no acepta responsabilidad por daños o pérdidas del material enviado. Los autores deberán remitir una versión electrónica al correo: revista@sah.org.ar

Descargas

Los datos de descargas todavía no están disponibles.